2-4-dinitrofluorobenzene-sulfonic-acid and Body-Weight

2-4-dinitrofluorobenzene-sulfonic-acid has been researched along with Body-Weight* in 4 studies

Other Studies

4 other study(ies) available for 2-4-dinitrofluorobenzene-sulfonic-acid and Body-Weight

ArticleYear
Preclinical Development of FA5, a Novel AMP-Activated Protein Kinase (AMPK) Activator as an Innovative Drug for the Management of Bowel Inflammation.
    International journal of molecular sciences, 2021, Jun-13, Volume: 22, Issue:12

    Acadesine (ACA), a pharmacological activator of AMP-activated protein kinase (AMPK), showed a promising beneficial effect in a mouse model of colitis, indicating this drug as an alternative tool to manage IBDs. However, ACA displays some pharmacodynamic limitations precluding its therapeutical applications. Our study was aimed at evaluating the in vitro and in vivo effects of FA-5 (a novel direct AMPK activator synthesized in our laboratories) in an experimental model of colitis in rats. A set of experiments evaluated the ability of FA5 to activate AMPK and to compare the efficacy of FA5 with ACA in an experimental model of colitis. The effects of FA-5, ACA, or dexamethasone were tested in rats with 2,4-dinitrobenzenesulfonic acid (DNBS)-induced colitis to assess systemic and tissue inflammatory parameters. In in vitro experiments, FA5 induced phosphorylation, and thus the activation, of AMPK, contextually to the activation of SIRT-1. In vivo, FA5 counteracted the increase in spleen weight, improved the colon length, ameliorated macroscopic damage score, and reduced TNF and MDA tissue levels in DNBS-treated rats. Of note, FA-5 displayed an increased anti-inflammatory efficacy as compared with ACA. The novel AMPK activator FA-5 displays an improved anti-inflammatory efficacy representing a promising pharmacological tool against bowel inflammation.

    Topics: AMP-Activated Protein Kinases; Animals; Benzofurans; Body Weight; Cell Line; Colon; Dinitrofluorobenzene; Drug Development; Electrophoresis, Gel, Two-Dimensional; Enzyme Activators; Gene Ontology; Inflammatory Bowel Diseases; Interleukin-10; Male; Malondialdehyde; Mice; Organ Size; Phosphorylation; Rats, Sprague-Dawley; Spleen; Tumor Necrosis Factor-alpha

2021
Adelmidrol, a Palmitoylethanolamide Analogue, as a New Pharmacological Treatment for the Management of Inflammatory Bowel Disease.
    Molecular pharmacology, 2016, Volume: 90, Issue:5

    Leukocyte infiltration, improved levels of intercellular adhesion molecule 1 (ICAM-1), and oxidative stress in the colon are the principal factors in inflammatory bowel disease. The goal of the current study was to explore the effects of adelmidrol, an analog of the anti-inflammatory fatty acid amide signaling molecule palmitoylethanolamide, in mice subjected to experimental colitis. Additionally, to clarify whether the protective action of adelmidrol is dependent on the activation of peroxisome proliferator-activated receptors (PPARs), we investigated the effects of a PPARγ antagonist, GW9662, on adelmidrol action. Adelmidrol (10 mg/kg daily, o.s.) was tested in a murine experimental model of colitis induced by intracolonic administration of dinitrobenzene sulfonic acid. Nuclear factor-κB translocation, cyclooxygenase-2, and phosphoextracellular signal-regulated kinase, as well as tumor necrosis factor-α and interleukin-1β, were significantly increased in colon tissues after dinitrobenzene sulfonic acid administration. Immunohistochemical staining for ICAM-1, P-selectin, nitrotyrosine, and poly(ADP)ribose showed a positive staining in the inflamed colon. Treatment with adelmidrol decreased diarrhea, body weight loss, and myeloperoxidase activity. Adelmidrol treatment, moreover, reduced nuclear factor-κB translocation, cyclooxygenase-2, and phosphoextracellular signal-regulated kinase expression; proinflammatory cytokine release; and the incidence of nitrotyrosine and poly(ADP)ribose in the colon. It also decreased the upregulation of ICAM-1 and P-selectin. Adelmidrol treatment produced a reduction of Bax and an intensification of Bcl-2 expression. This study clearly demonstrates that adelmidrol exerts important anti-inflammatory effects that are partly dependent on PPARγ, suggesting that this molecule may represent a new pharmacologic approach for inflammatory bowel disease treatment.

    Topics: Amides; Animals; Anti-Inflammatory Agents; Apoptosis; Body Weight; Colitis; Cyclooxygenase 2; Cytokines; Dicarboxylic Acids; Dinitrofluorobenzene; Ethanolamines; Extracellular Signal-Regulated MAP Kinases; Inflammatory Bowel Diseases; Intercellular Adhesion Molecule-1; Lipid Peroxidation; Male; Mice; NF-kappa B; P-Selectin; Palmitic Acids; Peroxidase; Phosphorylation; PPAR alpha; PPAR gamma; Receptor, Cannabinoid, CB2; Signal Transduction; Tyrosine

2016
Is Crohn's creeping fat an adipose tissue?
    Inflammatory bowel diseases, 2011, Volume: 17, Issue:3

    In human pathology, the "creeping fat" (CF) of the mesentery is unique to Crohn's disease (CD). CF is usually referred to as an ectopic extension of mesenteric adipose tissue (MAT). However, since no animal model developing CF has ever been established, very little is known about this type of fat-depot expansion and its role in the development of the disease.. We developed and standardized an experimental protocol in mice that reproducibly induces CF development when a severe colonic inflammation is obtained by intracolonic instillation of DNBS.. Macro-microscopic observations revealed a fatty appearance of CF. Yet when compared to MAT from the same animals, CF contains very little triglycerides, few adipocytes, and we observed a very low expression and protein levels of both adipose markers (hormone-sensitive lipase, perilipin) and adipocytokines (leptin, adiponectin). The decreased expression of perilipin in CF was also observed by immunohistochemistry. Conversely, the expression of proinflammatory and fibrous markers (Pref-1) was much higher in CF than in MAT. These observations were fully consistent with those made on CF recovered from five CD patients and compared with subcutaneous and mesenteric fat from the same patients.. Altogether, this work reports an original experimental mice model of CF. In this model we establish for the first time that CF only occurs in severe colonic inflammation and shows an inflammatory, fibrous but not an adipose pattern.

    Topics: Adipose Tissue; Animals; Blotting, Western; Body Weight; Colitis; Crohn Disease; Dinitrofluorobenzene; Enzyme-Linked Immunosorbent Assay; Humans; Immunoenzyme Techniques; Lipids; Male; Mesentery; Mice; Mice, Inbred BALB C; Peroxidase; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger

2011
The beta3-adrenoceptor agonist SR58611A ameliorates experimental colitis in rats.
    Neurogastroenterology and motility, 2008, Volume: 20, Issue:9

    Beta(3)-adrenoceptor agonists protect against experimental gastric ulcers. We investigated the effects of the beta(3)-adrenoceptor agonist SR58611A on 2,4-dinitrobenzene sulphonic acid-induced colitis in rats and analysed the expression of beta(3)-adrenoceptors in the colonic wall. SR58611A was administered orally (1-10 mg kg(-1)) for 7 days, starting the day before induction of colitis. Colitis was assessed by macroscopic and histological scores, tissue myeloperoxidase activity, interleukin-1beta (IL-1beta), interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-alpha) levels. Reverse transcription-polymerase chain reaction and immunohistochemical analysis were used to examine the expression of beta(3)-adrenoceptors. SR58611A significantly reduced the severity of colitis as well as the tissue levels of TNF-alpha, IL-1beta and IL-6. Colitis was associated with a decreased expression of beta(3)-adrenoceptor mRNA in the mucosal/submucosal layer of distal colon and this reduction was not affected by SR58611A. Immunohistochemical analysis revealed beta(3)-adrenoceptors within the muscularis externa, in myenteric neurons and nerve fibres and in the submucosa. beta(3)-Adrenoceptor immunoreactivity was decreased in inflamed tissues compared to controls, particularly in the myenteric plexus; this reduction was counteracted by SR58611A. Amelioration of experimental colitis by the selective beta(3)-adrenoceptor agonist SR58611A suggests that beta(3)-adrenoceptors may represent a therapeutic target in gut inflammation.

    Topics: Adrenergic beta-3 Receptor Agonists; Adrenergic beta-Agonists; Animals; Body Weight; Colitis; Colon; Cytokines; Dinitrofluorobenzene; Dose-Response Relationship, Drug; Humans; Inflammation; Male; Proto-Oncogene Proteins c-kit; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, beta-3; Tetrahydronaphthalenes

2008